RS52520B - Inhibitori akt i p70 s6 kinaze - Google Patents

Inhibitori akt i p70 s6 kinaze

Info

Publication number
RS52520B
RS52520B RS20120443A RSP20120443A RS52520B RS 52520 B RS52520 B RS 52520B RS 20120443 A RS20120443 A RS 20120443A RS P20120443 A RSP20120443 A RS P20120443A RS 52520 B RS52520 B RS 52520B
Authority
RS
Serbia
Prior art keywords
add
imidazol
phenyl
fluoro
ethyl
Prior art date
Application number
RS20120443A
Other languages
English (en)
Serbian (sr)
Inventor
Sajan Joseph
Robert Dean Dally
Timothy Alan Shepherd
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of RS52520B publication Critical patent/RS52520B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20120443A 2008-11-11 2009-11-03 Inhibitori akt i p70 s6 kinaze RS52520B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
PCT/US2009/063020 WO2010056563A1 (en) 2008-11-11 2009-11-03 Akt and p70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
RS52520B true RS52520B (sr) 2013-04-30

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120443A RS52520B (sr) 2008-11-11 2009-11-03 Inhibitori akt i p70 s6 kinaze

Country Status (36)

Country Link
US (1) US8148387B2 (cg-RX-API-DMAC10.html)
EP (1) EP2358710B1 (cg-RX-API-DMAC10.html)
JP (1) JP5432275B2 (cg-RX-API-DMAC10.html)
KR (1) KR101334460B1 (cg-RX-API-DMAC10.html)
CN (1) CN102216302B (cg-RX-API-DMAC10.html)
AR (1) AR074072A1 (cg-RX-API-DMAC10.html)
AU (1) AU2009314324B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0921916A2 (cg-RX-API-DMAC10.html)
CA (1) CA2743019C (cg-RX-API-DMAC10.html)
CO (1) CO6382114A2 (cg-RX-API-DMAC10.html)
CR (1) CR20110240A (cg-RX-API-DMAC10.html)
CY (1) CY1113409T1 (cg-RX-API-DMAC10.html)
DK (1) DK2358710T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2011000129A (cg-RX-API-DMAC10.html)
EA (1) EA018947B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP11011048A (cg-RX-API-DMAC10.html)
ES (1) ES2391704T3 (cg-RX-API-DMAC10.html)
HN (1) HN2011001247A (cg-RX-API-DMAC10.html)
HR (1) HRP20120738T1 (cg-RX-API-DMAC10.html)
IL (1) IL211940A (cg-RX-API-DMAC10.html)
JO (1) JO2822B1 (cg-RX-API-DMAC10.html)
MA (1) MA32776B1 (cg-RX-API-DMAC10.html)
MX (1) MX2011005000A (cg-RX-API-DMAC10.html)
MY (1) MY161461A (cg-RX-API-DMAC10.html)
NZ (1) NZ592062A (cg-RX-API-DMAC10.html)
PA (1) PA8846901A1 (cg-RX-API-DMAC10.html)
PE (1) PE20110807A1 (cg-RX-API-DMAC10.html)
PL (1) PL2358710T3 (cg-RX-API-DMAC10.html)
PT (1) PT2358710E (cg-RX-API-DMAC10.html)
RS (1) RS52520B (cg-RX-API-DMAC10.html)
SI (1) SI2358710T1 (cg-RX-API-DMAC10.html)
TN (1) TN2011000207A1 (cg-RX-API-DMAC10.html)
TW (1) TWI422587B (cg-RX-API-DMAC10.html)
UA (1) UA100190C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010056563A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201102549B (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021088B1 (ru) 2009-07-02 2015-04-30 Санофи Производные (6-оксо-1,6-дигидропиримидин-2-ил)амида, их получение и их фармацевтическое применение в качестве ингибиторов фосфорилирования akt (pkb)
ES2465094T3 (es) 2009-10-23 2014-06-05 Eli Lilly And Company Inhibidores de AKT
WO2012136776A1 (en) 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors
ES2547687T3 (es) * 2011-07-09 2015-10-08 Xuanzhu Pharma Co., Ltd. Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma
EP2755965B1 (en) * 2011-09-12 2017-07-26 Merck Patent GmbH Novel imidazole amines as modulators of kinase activity
CN103930407B (zh) 2011-09-12 2019-02-26 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
ES2620119T3 (es) * 2012-11-16 2017-06-27 Merck Patent Gmbh Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa
CA2890345A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Imidazol-piperidinyl derivatives as modulators of kinase activity
HK1218756A1 (zh) * 2013-03-11 2017-03-10 默克专利有限公司 用作激酶活性调节剂的6-[4-(1h-咪唑-2-基)哌啶-1-基]嘧啶-4-胺衍生物
KR20160110953A (ko) * 2014-02-11 2016-09-23 메르크 파텐트 게엠베하 키나아제 활성의 조절자로서의 피리미딘 이미다졸 아민
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
CA3024831C (en) * 2016-05-20 2021-06-08 Taiho Pharmaceutical Co., Ltd. Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative
JP2023520140A (ja) * 2020-03-17 2023-05-16 江蘇恒瑞医薬股▲ふん▼有限公司 縮合二環系誘導体、その調製方法及びその医薬的応用
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
JP2024535857A (ja) 2021-09-17 2024-10-02 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 縮合二環系誘導体の薬学的に許容される塩、結晶及びそれらの調製方法
EP4553078A1 (en) * 2022-07-05 2025-05-14 Taiho Pharmaceutical Co., Ltd. 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one and crystal of salt thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
EP3421471B1 (en) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
CN102216302B (zh) 2013-08-21
JO2822B1 (en) 2014-09-15
IL211940A0 (en) 2011-06-30
UA100190C2 (en) 2012-11-26
EA201170680A1 (ru) 2011-12-30
TWI422587B (zh) 2014-01-11
CO6382114A2 (es) 2012-02-15
DK2358710T3 (da) 2012-09-03
SI2358710T1 (sl) 2012-11-30
PL2358710T3 (pl) 2012-12-31
HK1158203A1 (en) 2012-07-13
JP2012508274A (ja) 2012-04-05
PA8846901A1 (es) 2010-06-28
PT2358710E (pt) 2012-10-01
MX2011005000A (es) 2011-05-25
AU2009314324A1 (en) 2010-05-20
KR101334460B1 (ko) 2013-12-02
DOP2011000129A (es) 2016-02-29
US8148387B2 (en) 2012-04-03
ECSP11011048A (es) 2011-06-30
CR20110240A (es) 2011-06-09
CY1113409T1 (el) 2016-06-22
JP5432275B2 (ja) 2014-03-05
ES2391704T3 (es) 2012-11-29
WO2010056563A1 (en) 2010-05-20
EA018947B1 (ru) 2013-11-29
HRP20120738T1 (hr) 2012-10-31
KR20110074578A (ko) 2011-06-30
AR074072A1 (es) 2010-12-22
CN102216302A (zh) 2011-10-12
EP2358710B1 (en) 2012-08-15
BRPI0921916A2 (pt) 2015-12-29
CA2743019C (en) 2013-08-13
TN2011000207A1 (en) 2012-12-17
HN2011001247A (es) 2013-05-20
TW201022268A (en) 2010-06-16
US20100120801A1 (en) 2010-05-13
PE20110807A1 (es) 2011-10-31
IL211940A (en) 2014-01-30
CA2743019A1 (en) 2010-05-20
AU2009314324B2 (en) 2013-06-20
MA32776B1 (fr) 2011-11-01
MY161461A (en) 2017-04-14
EP2358710A1 (en) 2011-08-24
ZA201102549B (en) 2012-09-26
NZ592062A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
EP2358710B1 (en) Akt and p70 s6 kinase inhibitors
AU2013295906B2 (en) Novel heteroaryl and heterocycle compounds, composition and methods thereof
EP3354652B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CA2687265C (en) P70 s6 kinase inhibitors
AU2010310786B2 (en) AKT inhibitors
EP2857403B1 (en) Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof
KR20130116358A (ko) Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
EP3478687A1 (en) Pyrazolopyrimidine derivatives as kinase inhibitor
JP2025535332A (ja) ｃＧＡＳ阻害剤としてのトリアゾール置換イミダゾ［１，２－ａ］ピリミジン
HK1158203B (en) Akt and p70 s6 kinase inhibitors
AU2017201801B2 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
HK1203499B (en) Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof